Navigation Links
Sinobiopharma Secures Rights to Seven Key Patents
Date:4/27/2009

NANJING, China, April 27 /PRNewswire-FirstCall/ -- Sinobiopharma Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin Board: SNBP) is pleased to announce that it has secured rights to seven key patents from Company CEO Dr. Lequn Huang and the patents' co-holders. The patents that will significantly enhance Sinobiopharma's ability to execute on its mission of bringing safe, low-cost, high-efficacy biopharmaceuticals to market.

The patents are for the following:

  1. Synthesis of amantadine hydrochloride
  2. Method for preparation of 17-acylsinomenine derivatives
  3. Preparation of 17-sulfonylsinomenine
  4. Preparation of N-substituted sinomenine
  5. Method for preparation of Sinomenine compound having dextro-rotary C ring-deficient morphinan skeleton
  6. Synthesis of Eplerenone from 11 -hydroxycanrenone
  7. Method for resolving tetrahydroisoquinoline racemate

Sinobiopharma will be applying these patents as well as using its own innovative applications of them in new drug development.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
2. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
3. Sinobiopharma, Inc. Appoints New Director of Marketing
4. Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
5. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
6. Aerovance Secures $38 Million in Equity Financing
7. VIA Pharmaceuticals Secures Financing Up to $10.0 Million
8. Pearl Therapeutics Secures $8 Million in Debt Financing
9. Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Northwest Biotherapeutics Secures $700,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove announced today ... National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts to work ... throughout the drug regulatory review process. , “Adding Diane Dorman is just the ...
(Date:2/9/2016)... , Feb. 9, 2016 This market ... the current and future prospects of the market in ... report include companies engaged in the manufacture of microbiology ... executive summary with a market snapshot providing the overall ... of this report. This section also provides the overall ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of ... in Life-Changing Camp Experiences ... affect the lives of children born with rare diseases, as well ... ) is announcing a new initiative designed to positively affect the ... future of rare disease care. --> To mark the ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
(Date:2/1/2016)... 1, 2016 Rising sales of ... global touchfree intuitive gesture control market size ... sales of consumer electronics coupled with new technological advancements ... size through 2020   --> ... new technological advancements to drive global touchfree intuitive gesture ...
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
Breaking Biology News(10 mins):